iQIYI, Inc. (IQ) — Earnings Call X-Ray
Our AI read all 28 of IQ's earnings calls (2018–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
C
Q4 2024
Calls Analyzed
28
2018–2025
Avg Candor
6.1/9
evasion 2.9/9
Call-by-call analysis
🔒 Q1 2025 earnings call
2025-05-21
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2025 call grade is ready
The full 37-point AI read of IQ's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
C
Q4 2024 earnings call
2025-02-18
move ±17%
Management gave no formal guidance against accelerating demand. The delivery was rich in specifics, promotional in tone.
Demand: acceleratingMargins: stablePricing: stable 4 analysts · 4 questions
⚑ Critic ammunition✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q3 2024 earnings call
2024-11-22
move ±16.4%
Management gave no formal guidance. The delivery was light on specifics.
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q2 2024 earnings call
2024-08-22
move ±20.4%
Management gave no formal guidance against mixed demand signals. The delivery was rich in specifics, promotional in tone.
Demand: mixedMargins: stablePricing: raising 4 analysts · 4 questions
⚑ Critic ammunition✓ Resolves doubts⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q1 2024 earnings call
2024-05-16
move ±19%
Management gave no formal guidance against mixed demand signals and expanding margins. The delivery was rich in specifics, promotional in tone.
Demand: mixedMargins: expandingPricing: raising 4 analysts · 4 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C+
Q4 2023 earnings call
2024-02-28
move ±11.1%
Management held guidance steady against steady demand and expanding margins. The delivery was rich in specifics, relaxed under questioning.
Guidance: maintainedDemand: stableMargins: expandingPricing: raisingCapex: increasing 3 analysts · 3 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
B
Q3 2023 earnings call
2023-11-21
move ±9.7%
Management held guidance steady against accelerating demand and expanding margins. The delivery was rich in specifics, relaxed under questioning.
Guidance: maintainedDemand: acceleratingMargins: expandingPricing: raisingCapex: increasing 5 analysts · 5 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
B+
Q2 2023 earnings call
2023-08-22
move ±14.7%
Management gave no formal guidance against accelerating demand and expanding margins. The delivery was rich in specifics, relaxed under questioning.
Demand: acceleratingMargins: expandingPricing: raising 5 analysts · 5 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q1 2023 |
2023-05-16 |
B+ |
raised | accelerating | expanding |
6/9 |
2/9 |
| Q4 2022 |
2023-02-22 |
B+ |
raised | accelerating | expanding |
6/9 |
2/9 |
| Q3 2022 |
2022-11-22 |
B |
maintained | accelerating | expanding |
7/9 |
2/9 |
| Q2 2022 |
2022-08-30 |
C+ |
raised | mixed | expanding |
6/9 |
3/9 |
| Q1 2022 |
2022-05-26 |
C+ |
maintained | stable | expanding |
7/9 |
2/9 |
| Q4 2021 |
2022-03-01 |
C+ |
raised | mixed | expanding |
7/9 |
3/9 |
| Q3 2021 |
2021-11-17 |
F |
none | mixed | stable |
6/9 |
3/9 |
| Q2 2021 |
2021-08-12 |
C |
maintained | stable | expanding |
6/9 |
3/9 |
| Q1 2021 |
2021-05-18 |
D |
maintained | mixed | expanding |
7/9 |
4/9 |
| Q4 2020 |
2021-02-18 |
D |
none | mixed | expanding |
6/9 |
3/9 |
| Q3 2020 |
2020-11-17 |
F |
maintained | slowing | expanding |
6/9 |
5/9 |
| Q2 2020 |
2020-08-18 |
F |
lowered | slowing | expanding |
6/9 |
5/9 |
| Q1 2020 |
2020-05-19 |
D |
maintained | mixed | contracting |
7/9 |
4/9 |
| Q4 2019 |
2020-02-27 |
D |
lowered | mixed | expanding |
6/9 |
2/9 |
| Q3 2019 |
2019-11-07 |
D |
lowered | slowing | contracting |
7/9 |
3/9 |
| Q2 2019 |
2019-08-21 |
D |
lowered | mixed | contracting |
7/9 |
2/9 |
| Q1 2019 |
2019-05-17 |
D |
maintained | mixed | contracting |
6/9 |
4/9 |
| Q4 2018 |
2019-02-22 |
C |
none | accelerating | contracting |
7/9 |
3/9 |
| Q3 2018 |
2018-10-31 |
D |
maintained | mixed | contracting |
6/9 |
4/9 |
| Q2 2018 |
2018-08-01 |
C+ |
maintained | accelerating | contracting |
6/9 |
3/9 |
Research question bank — earlier calls
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of IQ's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
C+
Q4 2021 earnings call
2022-03-01
2 more research questions answered NO
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← IPXL All “I” companies
IQEPF →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.